US Patent 6,194,445: Pramipexole Restless Legs Syndrome Claims, Scope, Expiration, and Patent Landscape

US Patent 6,194,445 covered the use of pramipexole and specified pramipexole salts for treating restless legs syndrome (RLS). Its central claim required four elements: an RLS patient, administration of an effective amount, a defined pramipexole chemical form, and a daily dose of about 0.001 to 10.0 mg. The patent term expired in 2018, eliminating current US infringement risk from the granted claims.

The patent was commercially important because it separated the RLS indication from pramipexole's earlier Parkinson's disease patents. It did not create a surviving composition-of-matter monopoly over pramipexole.

What does US Patent 6,194,445 claim?

Claim 1 is a method-of-treatment claim directed to RLS. Based on the claim language supplied, infringement requires the following limitations:

Claim element	Scope
Patient	A patient suffering from restless legs syndrome
Therapeutic act	Administration of an effective amount
Active ingredient	Pramipexole or one of the expressly identified forms
Covered forms	2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantiomer, its dihydrochloride, or its dihydrochloride monohydrate
Dose	About 0.001 to 10.0 mg per day
Claim type	Medical-use method claim

The chemical compound is pramipexole. The clinically used product is generally pramipexole dihydrochloride, including the monohydrate form used in commercial tablets.

The claim is broad in dose and does not appear, on its face, to limit treatment to a particular tablet strength, dosing schedule, release profile, administration route, disease severity, or diagnostic scale.

What chemical forms of pramipexole are covered?

The claim expressly identifies:

The pramipexole base or parent chemical entity.
The (-)-enantiomer.
The dihydrochloride salt.
The dihydrochloride monohydrate.

The inclusion of the (-)-enantiomer is commercially significant because pramipexole's pharmacological activity is associated primarily with that stereoisomer. The salt and hydrate language captures the pharmaceutical forms used in finished products.

A different salt, solvate, polymorph, prodrug, or chemically modified derivative would not necessarily fall within the literal language of claim 1. The result would depend on the precise claim construction and the applicability of the doctrine of equivalents.

How broad is the 0.001 to 10.0 mg/day limitation?

The claimed range is unusually broad relative to the FDA-approved RLS dosing range.

The FDA-approved Mirapex RLS regimen generally begins at 0.125 mg once daily, taken two to three hours before bedtime, with titration up to 0.5 mg once daily in the original RLS labeling. The patent's 0.001 to 10.0 mg/day range therefore encompasses the approved regimen and extends well below and above it.[2]

The term "about" introduces a potential tolerance issue. It prevents treating the endpoints as necessarily rigid numerical boundaries, but it does not make every dose outside the range infringing. Courts would evaluate the intrinsic evidence, prosecution history, technical meaning of "about," and whether the accused dose performs substantially the same function in substantially the same way.

Does the claim require a particular dosing schedule?

Not expressly. The claim states a daily dose rather than a specific administration interval. It therefore potentially covers:

Once-daily administration.
Divided daily dosing.
Immediate-release products.
Certain extended-release regimens, if the total daily dose and other limitations are met.
Administration by a route supported by the patent disclosure and legally encompassed by the claim.

A product label that instructs treatment of RLS with pramipexole within the claimed dose range would have presented a direct infringement issue during the patent term. After expiration, that issue no longer creates prospective US liability.

What does US Patent 6,194,445 not claim?

The claim does not expressly cover several categories of subject matter.

Composition of matter

The patent does not, based on the supplied claim, claim pramipexole as a new chemical compound. Earlier patents addressed the compound and related chemical entities. Patent 6,194,445 instead claims a therapeutic use.

Manufacturing processes

The claim does not cover synthesis, purification, crystallization, salt formation, particle engineering, or tablet manufacture. Separate process or solid-form patents would be required for those rights.

A specific formulation

The claim does not recite excipients, controlled-release matrices, coating systems, particle size, dissolution parameters, or tablet architecture. It is therefore not a formulation claim.

RLS diagnosis or clinical measurement

The claim requires treatment of a patient with RLS but does not specify diagnostic criteria, symptom scores, periodic limb movement measurements, or a particular disease subtype.

Combination therapy

The claim does not expressly require or exclude coadministration with another drug. A combination product containing pramipexole could fall within the claim if the other limitations were satisfied, but the claim would not independently protect the combination partner.

When did US Patent 6,194,445 expire?

US Patent 6,194,445 was issued on February 27, 2001. Its ordinary US patent term expired in 2018, calculated from the applicable nonprovisional filing date and subject to any recorded patent-term adjustment. Public patent records classify the patent as expired.[1]

Event	Date or status
US patent	6,194,445
Issue date	February 27, 2001
Patent holder	Boehringer Ingelheim-related entities
Subject	Pramipexole treatment of restless legs syndrome
Term status	Expired
Practical effect	No current US exclusivity from claim 1

The expiration date should be distinguished from FDA regulatory exclusivity. FDA exclusivity is a statutory marketing protection tied to approval of a drug application. It does not extend an expired patent.

What was the Orange Book status of pramipexole?

Mirapex was approved by the FDA for Parkinson's disease in 1997 and later received an indication for moderate-to-severe primary RLS in 2006.[2][3]

The relevant regulatory framework included:

The New Drug Application for Mirapex.
Orange Book patent listings for the branded product.
ANDA certifications by generic applicants.
Potential Paragraph IV challenges to listed patents.
A label carve-out for a patented method of use, where permitted.

A method-of-use patent can affect generic approval even when the active ingredient and composition patents have expired. Under the Hatch-Waxman framework, an ANDA applicant may certify that a listed patent is invalid or not infringed under Paragraph IV, or may seek approval with the patented indication omitted from the label.

For pramipexole, the commercial significance of the RLS patent was greatest during the period when generic manufacturers sought approval for Parkinson's disease while RLS remained a separately protected indication.

Did the patent block generic pramipexole?

It could have restricted an uncarved generic label that expressly included RLS during the patent term. It did not necessarily prevent approval of a generic product with:

A Parkinson's-only label.
A proper section viii label carve-out for the patented RLS use.
A successful Paragraph IV position.
A launch after patent expiration.

Once the patent expired, claim 1 no longer supplied a basis for preventing generic RLS labeling or RLS-directed prescribing.

What Paragraph IV challenges affected pramipexole?

Paragraph IV certification was the relevant Hatch-Waxman route for an ANDA applicant asserting that a listed patent was invalid, unenforceable, or not infringed.

The patent number alone does not establish the identity of a particular challenger, the filing date of a certification, or whether a case settled. Those facts must be taken from FDA ANDA records, district court complaints, docket entries, or settlement documents. The patent itself identifies the claimed invention, not the complete litigation history.

The legal risk profile was as follows:

Issue	Assessment
Active ingredient patent risk	Historical and largely expired
RLS method patent risk	Expired in 2018
Paragraph IV risk today	No current blocking effect from US 6,194,445
Label-carve-out relevance	Important before expiration
Generic RLS launch risk	Primarily historical for this patent
Current litigation leverage	None from the expired claim alone

What patent litigation and settlement issues were relevant?

A method-of-use patent such as US 6,194,445 could support litigation against:

An ANDA applicant with an RLS indication.
A generic label that directly instructed RLS treatment.
A distributor or manufacturer participating in a product launch after a Paragraph IV certification.

The principal defenses would have included:

Non-infringement because the generic label omitted RLS.
Invalidity for anticipation or obviousness.
Lack of enablement or written description, depending on the disclosure and prosecution record.
Claim construction arguments concerning the chemical form or dose.
Failure to prove induced infringement.
Patent expiration.

After 2018, expiration became dispositive for prospective infringement. Any historical settlement agreement would have to be examined separately for launch dates, authorized-generic provisions, supply restrictions, or non-patent commercial terms. The expiration of the patent does not itself disclose whether an earlier settlement existed.

How strong was the patent estate for pramipexole?

The estate was strongest when viewed as a layered portfolio:

Patent layer	Function	Commercial status
Compound patents	Protect pramipexole and related chemical entities	Historical foundational protection
RLS method patent	Protect use of pramipexole for RLS	Expired
Parkinson's method patents	Protect earlier therapeutic use	Expired or historically limited
Formulation patents	Protect release profile or dosage form, where applicable	Requires separate patent review
Manufacturing patents	Protect synthesis or solid-state processes	Requires separate patent review
Regulatory exclusivity	Protect FDA marketing rights for limited periods	Expired for the original product

The estate did not have the characteristics of a biologic exclusivity package. Pramipexole is a small molecule, so biosimilar rules do not apply. Generic applicants use the ANDA pathway rather than the biosimilar pathway.

How does the patent compare with formulation patents?

US Patent 6,194,445 is materially broader in therapeutic concept but narrower in claim category than a formulation patent.

A formulation patent may cover:

Extended-release pramipexole.
Specific tablet matrices.
Defined dissolution profiles.
Particular excipient ratios.
Controlled plasma exposure.
Once-daily delivery systems.

A formulation patent can remain relevant after a method-of-use patent expires if the generic product practices the protected formulation. Conversely, an immediate-release generic that avoids the formulation limitations may not face that barrier.

What generic entry risks exist for pramipexole?

The main entry scenarios were:

Scenario 1: Parkinson's indication first

A generic applicant could seek approval for Parkinson's disease while excluding the RLS indication from its label. This approach reduced exposure to the RLS method patent during its term.

Scenario 2: Full-label generic after expiration

After expiration of US 6,194,445, a generic applicant could seek or maintain RLS labeling without that patent creating a statutory barrier.

Scenario 3: Formulation-specific delay

A separate extended-release or formulation patent could delay a particular dosage form even after the RLS method patent expired. That risk is product-specific and cannot be attributed to US 6,194,445.

Scenario 4: Authorized generic or settlement launch

A brand company could permit an earlier launch through a license or authorized-generic arrangement. Such a commercial event would not change the legal expiration date.

What geographic coverage did the patent provide?

US Patent 6,194,445 provided rights only in the United States. It did not directly control:

European pramipexole sales.
Canadian RLS products.
Japanese products.
Manufacturing outside the United States.
Importation into the United States if the imported product practiced the claimed method, subject to applicable statutory rules.

Foreign counterparts had to be analyzed independently for filing dates, prosecution outcomes, claim scope, supplementary protection certificates, and expiration. The US expiration did not establish the status of corresponding European or Asian rights.

What manufacturing and intellectual-property barriers remain?

US 6,194,445 does not currently block pramipexole manufacture. Remaining barriers may include:

Regulatory approval requirements.
API quality and impurity controls.
Salt and hydrate control.
Stability and dissolution specifications.
Trademarks and trade dress.
Active formulation patents.
Manufacturing process patents.
Contractual restrictions.
Controlled supply-chain and pharmacovigilance obligations.

These are commercial and regulatory barriers, not surviving exclusivity under claim 1.

What was the revenue exposure associated with the patent?

The patent protected the RLS indication for Mirapex during a period when pramipexole already had a Parkinson's franchise. Its value therefore depended on:

RLS prevalence and diagnosis rates.
The proportion of prescriptions directed to RLS.
The branded product's share before generic entry.
The availability of a generic Parkinson's label without RLS.
The timing of full-label generic competition.
The presence of other dopamine agonists, including ropinirole and rotigotine.

The patent did not protect all pramipexole revenue. It protected only use of the covered pramipexole forms for RLS within the claimed therapeutic and dose parameters.

Key Takeaways

US Patent 6,194,445 is a method-of-use patent for treating RLS with pramipexole.
Claim 1 covers pramipexole, its (-)-enantiomer, the dihydrochloride, and the dihydrochloride monohydrate.
The claimed dose is about 0.001 to 10.0 mg/day.
The claim does not expressly cover the pramipexole molecule as a composition, a manufacturing process, or a specific formulation.
The patent issued on February 27, 2001 and expired in 2018.
The patent is no longer a current US barrier to generic RLS labeling.
Paragraph IV and label-carve-out strategies were historically relevant before expiration.
Biosimilar law does not apply because pramipexole is a small molecule.
Any remaining commercial risk must be assessed through separate formulation, process, solid-form, trademark, and regulatory records.

FAQs About US Patent 6,194,445 and Pramipexole

Can a generic manufacturer market pramipexole for RLS now?

Yes, US Patent 6,194,445 no longer blocks RLS marketing because its patent term expired in 2018. Separate regulatory or formulation barriers could still apply.

Does US Patent 6,194,445 cover Mirapex ER?

Not based on the supplied claim. Claim 1 does not recite an extended-release formulation, dissolution profile, or delivery system. Mirapex ER must be assessed against separate formulation and regulatory records.

Is pramipexole subject to biosimilar competition?

No. Pramipexole is a chemically synthesized small molecule and competes through the generic drug pathway, principally under an ANDA.

Did the patent protect the active ingredient itself?

No. The supplied claim is a treatment method claim. Earlier composition patents, not claim 1 of US 6,194,445, provided the principal compound protection.

Can a company still sue over conduct that occurred before patent expiration?

Potentially, subject to applicable limitation periods, standing, proof of infringement, validity defenses, and the specific procedural history. The expiration of the patent ends prospective exclusivity but does not automatically resolve every historical claim.

References

United States Patent and Trademark Office. (2001). United States Patent No. 6,194,445: Treatment of restless legs syndrome with pramipexole.
U.S. Food and Drug Administration. (2006). Mirapex prescribing information: Pramipexole dihydrochloride tablets. Boehringer Ingelheim Pharmaceuticals, Inc.
U.S. Food and Drug Administration. (1997). Drugs@FDA: Mirapex application and approval history.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
United States Code, 35 U.S.C. §§ 154, 271, 355.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	197 01 619	Jan 17, 1997

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	281165	⤷ Start Trial
Australia	6016898	⤷ Start Trial
Australia	723119	⤷ Start Trial
Bulgaria	103543	⤷ Start Trial
Bulgaria	64614	⤷ Start Trial
Canada	2275379	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,194,445

Summary for Patent: 6,194,445